✅ Model Answer: • Radiographic finding: Dystrophic calcifications (calcinosis cutis) – dense, irregular, nodular or sheet-like calcifications in the soft tissues around the knee joint.
• Associated condition: Juvenile dermatomyositis (JDM).
• Significance: A common complication of JDM, especially with delayed treatment or anti-NXP2 antibody.

✅ Model Answer: • Calcinosis cutis: Deposition of calcium salts (hydroxyapatite) in the skin, subcutaneous tissue, and muscle.
• Pathophysiology in JDM: Dystrophic calcification – occurs in damaged tissues due to chronic inflammation and vasculopathy. In JDM, immune-mediated microangiopathy leads to tissue necrosis, which creates a microenvironment conducive to calcium deposition (normal calcium and phosphate metabolism).
• It is a marker of chronic, inadequately treated disease.

✅ Model Answer: • Risk factors for calcinosis in JDM:
- Delayed diagnosis and treatment: The most important modifiable risk factor.
- Anti-NXP2 (MJ) autoantibody: Strongly associated with calcinosis.
- Severe disease: More extensive muscle and skin involvement.
- Chronic inflammation: Persistent disease activity.
- Younger age at onset: Children <5 years are at higher risk.
- Inadequate immunosuppression.

✅ Model Answer: • Common sites:
- Periarticular areas: Knees (most common), elbows, hips, shoulders.
- Hands: Fingers, wrists.
- Buttocks.
- Trunk: Chest, abdomen, back.
- Less common: Eyelids, ears, oral mucosa.
• Calcifications are often bilateral and symmetric, but can be asymmetric.

✅ Model Answer: • Clinical manifestations:
- Firm, subcutaneous nodules or plaques: Often painless initially.
- Pain and tenderness: As calcifications enlarge or become inflamed.
- Joint stiffness and contractures: Especially when periarticular.
- Skin ulceration: Calcifications can erode through the skin, leading to discharging chalky material (calcium hydroxyapatite).
- Secondary infection: Ulcerated areas can become infected.
- Functional impairment: Limitation of joint movement, difficulty walking.
- Cosmetic concerns.

✅ Model Answer: • Best imaging modality: Plain radiograph (X-ray).
- X-ray is the most sensitive and specific for detecting calcifications.
- Findings: Dense, irregular, nodular, linear, or sheet-like opacities in the soft tissues.
- Other imaging:
- Ultrasound: Can detect superficial calcifications and guide biopsy.
- CT scan: Useful for extensive or deep calcifications.
- MRI: May show calcifications as areas of low signal on all sequences, but X-ray is superior.

✅ Model Answer: • Anti-NXP2 (MJ) antibody:
- A myositis-specific antibody found in ~10-15% of JDM patients.
- Strongly associated with calcinosis: Patients with anti-NXP2 have a significantly higher risk of developing calcinosis cutis (up to 70-80%).
- Also associated with more severe disease, muscle weakness, and joint contractures.
- Clinical significance: Testing for anti-NXP2 helps identify patients at risk for calcinosis, allowing for more aggressive monitoring and treatment.

✅ Model Answer: • Management focuses on controlling the underlying JDM:
- Optimize immunosuppression: Escalate therapy with methotrexate, IVIG, rituximab, mycophenolate, or other agents to reduce inflammation and prevent further calcification.
- No proven therapy for calcinosis itself: Treatments are largely anecdotal and not consistently effective.
- Potential therapies (anecdotal):
- Bisphosphonates: Pamidronate, alendronate – may reduce progression in some cases.
- Diltiazem: Calcium channel blocker – may inhibit calcium deposition.
- TNF inhibitors: Etanercept – may reduce inflammation.
- Sodium thiosulfate: May dissolve calcifications (limited evidence).
- Surgical excision: For focal, painful, or ulcerated lesions.
- Wound care: For ulcerated lesions with infection.

✅ Model Answer: • Bisphosphonates (pamidronate, alendronate):
- Mechanism: Inhibit osteoclast-mediated bone resorption and may reduce calcium deposition in soft tissues.
- Evidence: Some case series and small studies suggest that bisphosphonates can reduce progression or even improve calcinosis in JDM.
- Dose (pamidronate): 1 mg/kg/day for 3 days, repeated monthly, or 0.5-1 mg/kg/day for 3 consecutive days every 3 months (pediatric use off-label).
- Side effects: Transient fever, flu-like symptoms, hypocalcemia (monitor calcium and vitamin D).
- Not first-line: Used as adjunctive therapy in refractory calcinosis.

✅ Model Answer: • Complications:
- Pain and discomfort: Especially with pressure or movement.
- Joint contractures: Periarticular calcifications can limit joint mobility.
- Skin ulceration: Calcifications can erode through the skin, discharging chalky, white material.
- Secondary bacterial infection: Ulcerated areas are prone to infection.
- Functional impairment: Difficulty walking, using hands, or performing activities of daily living.
- Cosmetic disfigurement.
- Chronic pain and disability: Reduces quality of life.
- Calcinosis may persist even after the underlying JDM is controlled.

✅ Model Answer: • Calcinosis in JDM (dystrophic calcification):
- Occurs in damaged or necrotic tissues.
- Calcium and phosphate levels are normal.
- Results from local tissue injury (inflammation, vasculopathy).
- Common in JDM, CREST syndrome, and other connective tissue diseases.
• Metastatic calcification:
- Occurs in otherwise normal tissues.
- Calcium and phosphate levels are elevated (e.g., chronic kidney disease, hyperparathyroidism, hypervitaminosis D).
- Affects kidneys, blood vessels, lungs, and stomach.
- Key difference: Calcinosis in JDM has normal calcium/phosphate; metastatic calcification has abnormal levels.

✅ Model Answer: • Ultrasound role:
- Can detect superficial calcifications and assess their extent.
- Can differentiate between calcinosis and other soft tissue masses.
- Useful for guiding biopsy or aspiration of lesions.
- Doppler ultrasound can assess for associated inflammation (hyperemia).
- Advantages: No radiation, readily available, can be used for follow-up.
- Limitations: Less sensitive than X-ray for deep or tiny calcifications; operator-dependent.

✅ Model Answer: • "Your child has developed calcinosis – calcium deposits in the skin and muscles – as a complication of juvenile dermatomyositis. This happens when the inflammation damages tissues, leading to calcium deposition."
• "It is more common in children who started treatment late or have a specific antibody (anti-NXP2)."
• "The most important step is to ensure the underlying JDM is well-controlled with medications like methotrexate or IVIG. This can prevent new calcifications from forming."
• "There is no proven cure for existing calcifications, but we can try medications like bisphosphonates to slow their growth. For painful or ulcerated lesions, we may consider surgical removal."
• "Calcinosis can cause pain, stiffness, and sometimes skin ulcers. We will work with a multidisciplinary team to manage these symptoms."
• "This is a chronic process, but with good disease control, we can minimize its impact."

✅ Model Answer: • TNF inhibitors (etanercept):
- Indications: Used as a steroid-sparing agent in refractory JDM.
- Mechanism: Blocks tumor necrosis factor-α, a pro-inflammatory cytokine involved in the pathogenesis of JDM.
- Role in calcinosis: Some case reports suggest that TNF inhibitors may slow the progression of calcinosis by reducing inflammation.
- Evidence: Limited; not a first-line agent. Used when other therapies have failed.
- Side effects: Injection site reactions, increased risk of infections, autoimmune reactions.

✅ Model Answer: • Prognosis: Calcinosis is a marker of more severe JDM and is associated with increased morbidity.
- Calcinosis may persist even after the underlying myositis is controlled.
- Long-term functional impairment: Joint contractures and pain can lead to disability.
- Risk of recurrence: If JDM relapses, calcinosis can worsen.
- Early aggressive treatment: Reduces the risk of developing calcinosis; once present, it is difficult to reverse.
- Quality of life: Can be significantly impacted by pain, ulceration, and cosmetic concerns.
- With multidisciplinary care (rheumatology, physical therapy, wound care), outcomes can be optimized.